Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Phase 1

Terminated

Conditions: Multiple Myeloma
Plasma Cell Neoplasm

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Drug: Anticoagulants

Registration Number: NCT00790842

Lead Sponsor: PrECOG, LLC.

Brief Summary: Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction.

Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.

Detailed Description: Multiple Myeloma (MM) affects approximately 20,000 Americans annually and remains an incurable hematologic malignancy characterized by frequent early response followed by universal treatment relapse necessitating multiple sequential therapeutic regimens. Until recently, few effective therapies existed. Several novel agents for MM have now become available including the immunomodulatory drugs thalidomide, lenalidomide, as well as the proteasome inhibitor, bortezomib. Each of these agents is undergoing extensive clinical evaluation in combination with other therapies to produce unprecedented response rates in newly diagnosed and relapsed MM. Lenalidomide has proven to be a highly effective treatment agent, particularly when used in combination with dexamethasone but is renally excreted and little information is available about its use in myeloma patients with impaired kidney function (20% have renal failure at some time after diagnosis). Defining a safe and effective dose of lenalidomide to use is a critical step in MM treatment.

OUTLINE: This is a Phase I, dose-escalation study of lenalidomide followed by a Phase II study. Patients are stratified according to degree of renal dysfunction (moderate \[creatinine clearance 30-60 mL/min\] vs severe \[creatinine clearance \<30 mL/min and does not require dialysis\] vs end-stage renal disease \[creatinine clearance \<30 mL/min and requires dialysis\]).

Patients receive oral lenalidomide on days 1-21 and low-dose oral dexamethasone 40 mg on days 1, 8, 15, and 22. There is a 7 day rest (days 22-28) from lenalidomide. Each cycle is 28 days and repeated in the absence of disease progression or unacceptable toxicity.

Patients enrolled in the phase II portion of the study will undergo blood sample collection periodically for pharmacokinetic analysis of lenalidomide (Mayo Clinic sites only).

After completion of study treatment, patients are followed every 6 months for up to 3 years.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 63

Inclusion Criteria

Diagnosed with previously treated multiple myeloma.
Measurable disease assessed by one of the following ≤21 days prior to registration:
- Serum monoclonal protein ≥1 g by protein electrophoresis
- Urine monoclonal protein >200 mg on 24 hour electrophoresis
- Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio
- Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease)
- If both serum and urine m-components are present, both must be followed in order to evaluate response.
All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ≥2 weeks prior to registration.
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Acceptable organ and marrow function ≤21 days prior to registration:
- Absolute neutrophil count (ANC) ≥1000/mm³
- Platelet count ≥75,000/mm³
- Total bilirubin ≤2 mg/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal
Renal impairment at baseline as measured by serum creatinine clearance (CrCl) ≤60 mL/min ≤21 days prior to registration.
Females of Childbearing Potential (FCBP) must have a negative pregnancy test within 10-14 days and again within 24 hours of starting Cycle 1 and must use an effective double-method contraception for ≥28 days prior to, during, and for ≥28 days after completion of study therapy.
Able to take required prophylactic anticoagulation.
Able to understand and willingness to sign a written informed consent.
Willing to provide blood samples for research purposes (Mayo Clinic sites only).
If previously received lenalidomide, demonstration of clinical response of any duration or stable disease with progression-free interval of ≥6 months from start of that therapy.

Exclusion Criteria

Concurrent use of other anti-cancer agents or treatments. Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to 20 mg of Prednisone per day as long as the dose has not been adjusted upwards in past 2 weeks prior to study registration.
Uncontrolled intercurrent illness including, but not limited to, any of the following:
- Ongoing or active infection requiring IV antibiotics
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Uncontrolled cardiac arrhythmia
- Psychiatric illness/social situation that would limit compliance with study requirements.
Any of the following as this regimen may be harmful to a developing fetus or nursing child:
- Pregnant women
- Breast-feeding women
- Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception.
HIV-positive patients on combination antiretroviral therapy.
Known hypersensitivity to thalidomide or other immunomodulatory drugs.
History of Stevens-Johnson syndrome characterized by a desquamating rash while taking thalidomide or similar drugs.
Other active malignancy except for non melanoma skin cancer or in situ cervical or breast cancer.
Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A - CrCl 30-60 mL/min	Anticoagulants	Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group B, CrCl < 30 mL/min	Anticoagulants	Creatinine clearance \< 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group C, CrCl < 30 mL/min, on dialysis	Anticoagulants	Creatinine clearance \< 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group A - CrCl 30-60 mL/min	Lenalidomide	Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group A - CrCl 30-60 mL/min	Dexamethasone	Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group B, CrCl < 30 mL/min	Lenalidomide	Creatinine clearance \< 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group B, CrCl < 30 mL/min	Dexamethasone	Creatinine clearance \< 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group C, CrCl < 30 mL/min, on dialysis	Lenalidomide	Creatinine clearance \< 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
Group C, CrCl < 30 mL/min, on dialysis	Dexamethasone	Creatinine clearance \< 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.

Primary Outcome Measures

Name	Time	Method
Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy	First cycle of therapy (28 days)	Dose Limiting Toxicity (DLT) was defined as any of the following events determined by the investigator to be possibly, probably, or definitely related to lenalidomide within the first cycle of therapy irrespective of whether the adverse events resolved: * Grade 3 or higher neutropenia with fever ≥38.5 degrees C * Grade 4 neutropenia ≥7 days * Grade 4 or higher thrombocytopenia * Other non-hematologic Grade 4 or higher adverse event not present prior to starting therapy or not due to underlying cause
Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]	56 months	Per International Myeloma Working Group criteria, complete response (CR): negative immunofixation of serum and urine, normalization of free light chain (FLC) ratio if at study entry FLC was only measurable non-bone parameter, \<5% plasma cells in bone marrow, disappearance of any soft tissue plasma cytomas; stringent complete response (sCR): all of above, + normal serum FLC ratio in all patients and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; partial response (PR): \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \< 200 mg per 24 hours, \>=50% decrease in difference between involved and uninvolved FLC levels or a 50% decrease in level of involved FLC with 50% decrease in ratio, \>=50% reduction in bone marrow plasma cells, if baseline percentage was \>=30%, \>=50% reduction in size of soft tissue plasmacytoma; very good partial response (VGPR): PR + improvements in serum and urine M-components

Secondary Outcome Measures

Name	Time	Method
Overall Survival Time	56 months	Overall survival is the time from registration to death from any cause. Patients alive at the time of analysis were censored at the date last known alive.
Duration of Response	56 months	Duration of response was defined as time between the onset of response and disease progression in months, among patients treated at the recommended phase II dose who experienced a response to treatment. Per criteria of the International Myeloma Working Group, progressive disease was defined as one of the following: increase of 25% from best confirmed response in serum M-component, urine M-component, free light chain (FLC), bone marrow plasma cell percentage, or development of new or increase in size of bone lesions or soft tissue plasma cytomas. Development of hypercalcemia that can be attributed solely to the myeloma also constituted progression.
Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient	56 months	The highest degree of any adverse event experienced by each patient, as assessed by NCI CTCAE Version 4, with an attribution of possibly, probably, or definitely related to treatment. Reportable adverse events included those occurring while on treatment or within 30 days of the end of treatment.
Renal Function Over Time	56 months	To describe renal function over time and to evaluate the safety profile of a onetime increase in lenalidomide dose at least 2 cycles after start of treatment due to improved renal function.
Pharmacokinetics of Lenalidomide in Impaired Renal Function	56 months	To determine the pharmacokinetics of lenalidomide administration in myeloma patients with impaired renal function (pharmacokinetic analysis will be performed in up to 12 consented Mayo Clinic subjects treated during the Phase II component of the trial (only).
Progression-free Survival	56 months	Progression-free survival is the time from registration to disease progression or death. Patients alive without disease progression were censored at the time of the last disease assessment.

Trial Locations

Locations (16): Metro MN CCOP
🇺🇸
Saint Louis Park, Minnesota, United States
Emory University Winship Cancer
🇺🇸
Atlanta, Georgia, United States
Siouxland Hematology Oncology Associates
🇺🇸
Sioux City, Iowa, United States
Waukesha Memorial Hospital (ProHealth Care)
🇺🇸
Waukesha, Wisconsin, United States
Mayo Clinic in Arizona
🇺🇸
Scottsdale, Arizona, United States
McFarland Clinic
🇺🇸
Ames, Iowa, United States
Kinston Medical Specialists
🇺🇸
Kinston, North Carolina, United States
University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
WVU Mary Babb Randolph Cancer Center
🇺🇸
Morgantown, West Virginia, United States
Gundersen Lutheran
🇺🇸
La Crosse, Wisconsin, United States
Aurora Cancer Center
🇺🇸
Wauwatosa, Wisconsin, United States
Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor
🇺🇸
Ann Arbor, Michigan, United States
University of IL at Chicago
🇺🇸
Chicago, Illinois, United States
Reading Hospital and Medical Center
🇺🇸
West Reading, Pennsylvania, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Missouri Valley Cancer Consortium
🇺🇸
Omaha, Nebraska, United States